

Hasan S Jafri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8224581/publications.pdf>

Version: 2024-02-01

70
papers

5,445
citations

81900

39
h-index

85541

71
g-index

72
all docs

72
docs citations

72
times ranked

5583
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses. <i>Journal of Infectious Diseases</i> , 2007, 195, 1126-1136.	4.0	357
2	A Systematic Review of Risk Factors Associated with Surgical Site Infections among Surgical Patients. <i>PLoS ONE</i> , 2013, 8, e83743.	2.5	290
3	Infections Due to <i>Aspergillus terreus</i> : A Multicenter Retrospective Analysis of 83 Cases. <i>Clinical Infectious Diseases</i> , 2004, 39, 192-198.	5.8	276
4	Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease. <i>Journal of Pediatrics</i> , 2008, 153, 833-838.e6.	1.8	260
5	Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 115-122.	2.0	239
6	Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein. <i>Journal of Infectious Diseases</i> , 1998, 178, 1555-1561.	4.0	231
7	Clinical Chorioamnionitis, Elevated Cytokines, and Brain Injury in Term Infants. <i>Pediatrics</i> , 2002, 110, 673-680.	2.1	199
8	Respiratory Syncytial Virus Induces Pneumonia, Cytokine Response, Airway Obstruction, and Chronic Inflammatory Infiltrates Associated with Long-Term Airway Hyperresponsiveness in Mice. <i>Journal of Infectious Diseases</i> , 2004, 189, 1856-1865.	4.0	159
9	Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1398-1408.	9.1	157
10	MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14046-14051.	7.1	135
11	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 415-420.	2.0	135
12	A Randomized, Double-Blind, Placebo-Controlled Trial of Dexamethasone in Severe Respiratory Syncytial Virus (RSV) Infection: Effects on RSV Quantity and Clinical Outcome. <i>Journal of Infectious Diseases</i> , 2002, 185, 1222-1228.	4.0	134
13	Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 869-875.	3.2	131
14	Mobilization of Plasmacytoid and Myeloid Dendritic Cells to Mucosal Sites in Children with Respiratory Syncytial Virus and Other Viral Respiratory Infections. <i>Journal of Infectious Diseases</i> , 2005, 191, 1105-1115.	4.0	127
15	A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented <i>Candida</i> or <i>Aspergillus</i> Infections in Pediatric Patients. <i>Pediatrics</i> , 2009, 123, 877-884.	2.1	123
16	Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4116-4123.	3.2	121
17	Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	106
18	<i>Mycoplasma pneumoniae</i> Induces Chronic Respiratory Infection, Airway Hyperreactivity, and Pulmonary Inflammation: a Murine Model of Infection-Associated Chronic Reactive Airway Disease. <i>Infection and Immunity</i> , 2002, 70, 649-654.	2.2	105

#	ARTICLE	IF	CITATIONS
19	The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 290-295.	3.0	101
20	Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 1089-1093.	2.0	100
21	Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4700-4707.	3.2	99
22	Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1811-1822.	3.2	96
23	A pilot clinical trial of a recombinant ricin vaccine in normal humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2268-2273.	7.1	95
24	Elevated Cytokine and Chemokine Levels and Prolonged Pulmonary Airflow Resistance in a Murine <i>Mycoplasma pneumoniae</i> Pneumonia Model: a Microbiologic, Histologic, Immunologic, and Respiratory Plethysmographic Profile. <i>Infection and Immunity</i> , 2001, 69, 3869-3876.	2.2	92
25	Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1450-1456.	3.2	82
26	Pharmacodynamics of Vancomycin for the Treatment of Experimental Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 876-881.	3.2	81
27	Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 330-334.	2.0	78
28	Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. <i>Journal of Infectious Diseases</i> , 2018, 217, 24-34.	4.0	76
29	Pharmacodynamics of Gatifloxacin in Cerebrospinal Fluid in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2650-2655.	3.2	72
30	Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 457-463.	1.0	65
31	Antibiotic Therapy for Nontuberculous Mycobacterial Cervicofacial Lymphadenitis. <i>Laryngoscope</i> , 2005, 115, 1746-1751.	2.0	64
32	SUCCESSFUL MEDICAL TREATMENT OF CUTANEOUS ASPERGILLOSIS IN A PREMATURE INFANT USING LIPOSOMAL AMPHOTERICIN B, VORICONAZOLE AND MICAFUNGIN. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 364-366.	2.0	56
33	Distribution of Respiratory Syncytial Virus Subtypes A and B Among Infants Presenting to the Emergency Department With Lower Respiratory Tract Infection or Apnea. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 335-340.	2.0	55
34	Efficacy and safety of suvatroxumab for prevention of <i>Staphylococcus aureus</i> ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1313-1323.	9.1	46
35	Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of <i>Mycoplasma pneumoniae</i> -Induced Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1614-1620.	3.2	45
36	Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. <i>Virology Journal</i> , 2005, 2, 46.	3.4	45

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics and Pharmacodynamics of Linezolid in Children With Cystic Fibrosis. <i>Pediatric Pulmonology</i> , 2009, 44, 148-154.	2.0	45
38	Herpes Simplex Virus Encephalitis During Suppressive Therapy With Acyclovir in a Premature Infant. <i>Pediatrics</i> , 2005, 115, 804-809.	2.1	44
39	Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 651-655.	3.0	43
40	Respiratory Syncytial Virus Persistence in the Lungs Correlates with Airway Hyperreactivity in the Mouse Model. <i>Journal of Infectious Diseases</i> , 2008, 198, 1435-1443.	4.0	43
41	Characterization of Alpha-Toxin <i>hla</i> Gene Variants, Alpha-Toxin Expression Levels, and Levels of Antibody to Alpha-Toxin in Hemodialysis and Postsurgical Patients with <i>Staphylococcus aureus</i> Bacteremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 227-236.	3.9	42
42	<i>Staphylococcus aureus</i> Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5312-5321.	3.2	41
43	Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial. <i>Pediatric Allergy and Immunology</i> , 2009, 20, 477-485.	2.6	40
44	Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental <i>Escherichia coli</i> Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3092-3097.	3.2	38
45	Respiratory Syncytial Virus Infections: Old Challenges and New Opportunities. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, S189-S197.	2.0	37
46	SAFETY EXPERIENCE WITH CASPOFLUNGIN IN PEDIATRIC PATIENTS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 1132-1135.	2.0	36
47	Healthcare utilization and costs associated with <i>S. aureus</i> and <i>P. aeruginosa</i> pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database. <i>BMC Health Services Research</i> , 2015, 15, 241.	2.2	30
48	Impact of Cethromycin (ABT-773) Therapy on Microbiological, Histologic, Immunologic, and Respiratory Indices in a Murine Model of <i>Mycoplasma pneumoniae</i> Lower Respiratory Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2897-2904.	3.2	29
49	Respiratory Syncytial Virus Persistence. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, S60-S62.	2.0	29
50	Fluoroquinolones in Paediatrics. <i>Drugs</i> , 1999, 58, 43-48.	10.9	25
51	Alternatives to antibiotics. <i>Intensive Care Medicine</i> , 2016, 42, 2034-2036.	8.2	24
52	Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against <i>Staphylococcus aureus</i> alpha toxin. <i>Clinical and Translational Immunology</i> , 2018, 7, e1009.	3.8	24
53	Role of chemokines in respiratory syncytial virus disease. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 454-456.	2.0	23
54	Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 1-7.	2.0	21

#	ARTICLE	IF	CITATIONS
55	Treatment of respiratory syncytial virus: antiviral therapies. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S89-S93.	2.0	19
56	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S46-S51.	5.8	19
57	Efficacy of Gatifloxacin in Experimental Escherichia coli Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1805-1807.	3.2	18
58	Serious Early Childhood Wheezing After Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm Infants. <i>Clinical Therapeutics</i> , 2010, 32, 2422-2432.	2.5	18
59	Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model. <i>Virology Journal</i> , 2007, 4, 109.	3.4	17
60	Risk prediction for Staphylococcus aureus surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial. <i>PLoS ONE</i> , 2018, 13, e0193445.	2.5	17
61	Title is missing!. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S89-S93.	2.0	14
62	Antibody-based therapy to combat Staphylococcus aureus infections. <i>Clinical Microbiology and Infection</i> , 2017, 23, 219-221.	6.0	14
63	Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 811-816.	3.0	13
64	New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 346-358.	2.1	11
65	Respiratory Syncytial Virus: Old Challenges and New Approaches. <i>Pediatric Annals</i> , 2005, 34, 62-68.	0.8	9
66	DIAGNOSTIC VIROLOGY PRACTICES FOR RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA VIRUS AMONG CHILDREN IN THE HOSPITAL SETTING: A NATIONAL SURVEY. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 956-958.	2.0	8
67	Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation. <i>Infectious Diseases and Therapy</i> , 2014, 3, 203-214.	4.0	6
68	Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity. <i>Infectious Diseases and Therapy</i> , 2014, 3, 339-347.	4.0	4
69	Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	3.9	1
70	Caspofungin Versus Liposomal Amphotericin B. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 986-987.	2.0	0